Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients with advanced solid malignancies (ASM) Molina, J., Wakelee, H. A., Fehling, J. M., Lensingi, J. L., Calcagni, J., Funke, R. F., Miles, D., Sikic, B. I. AMER ASSOC CANCER RESEARCH. 2007: 3508S–3509S
View details for Web of Science ID 000251969000535